NSEI:POLYMED

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Poly Medicure Limited manufactures and sells medical devices in India and internationally.


Snowflake Analysis

Outstanding track record with flawless balance sheet.


Similar Companies

Share Price & News

How has Poly Medicure's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: POLYMED's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.9%

POLYMED

12.2%

IN Medical Equipment

1.8%

IN Market


1 Year Return

48.3%

POLYMED

40.9%

IN Medical Equipment

-22.6%

IN Market

Return vs Industry: POLYMED exceeded the Indian Medical Equipment industry which returned 40.9% over the past year.

Return vs Market: POLYMED exceeded the Indian Market which returned -22.6% over the past year.


Shareholder returns

POLYMEDIndustryMarket
7 Day10.9%12.2%1.8%
30 Day28.4%30.6%-0.4%
90 Day-2.6%2.8%-19.9%
1 Year50.7%48.3%42.7%40.9%-21.1%-22.6%
3 Year42.2%38.5%31.9%28.9%-11.4%-16.2%
5 Year24.2%18.4%10.4%6.4%9.4%-0.8%

Price Volatility Vs. Market

How volatile is Poly Medicure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Poly Medicure undervalued compared to its fair value and its price relative to the market?

27.02x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: POLYMED (₹289.5) is trading above our estimate of fair value (₹66.53)

Significantly Below Fair Value: POLYMED is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: POLYMED is poor value based on its PE Ratio (27x) compared to the Medical Equipment industry average (15.4x).

PE vs Market: POLYMED is poor value based on its PE Ratio (27x) compared to the Indian market (9.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate POLYMED's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: POLYMED is overvalued based on its PB Ratio (6.3x) compared to the IN Medical Equipment industry average (0.6x).


Next Steps

Future Growth

How is Poly Medicure forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Poly Medicure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Poly Medicure performed over the past 5 years?

9.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: POLYMED has high quality earnings.

Growing Profit Margin: POLYMED's current net profit margins (13.8%) are higher than last year (11.3%).


Past Earnings Growth Analysis

Earnings Trend: POLYMED's earnings have grown by 9.6% per year over the past 5 years.

Accelerating Growth: POLYMED's earnings growth over the past year (42.1%) exceeds its 5-year average (9.6% per year).

Earnings vs Industry: POLYMED earnings growth over the past year (42.1%) exceeded the Medical Equipment industry 21.7%.


Return on Equity

High ROE: POLYMED's Return on Equity (23.2%) is considered high.


Next Steps

Financial Health

How is Poly Medicure's financial position?


Financial Position Analysis

Short Term Liabilities: POLYMED's short term assets (₹3.4B) exceed its short term liabilities (₹2.0B).

Long Term Liabilities: POLYMED's short term assets (₹3.4B) exceed its long term liabilities (₹1.1B).


Debt to Equity History and Analysis

Debt Level: POLYMED's debt to equity ratio (35.6%) is considered satisfactory.

Reducing Debt: POLYMED's debt to equity ratio has reduced from 41.2% to 35.6% over the past 5 years.

Debt Coverage: POLYMED's debt is well covered by operating cash flow (82.3%).

Interest Coverage: POLYMED's interest payments on its debt are well covered by EBIT (17x coverage).


Balance Sheet


Next Steps

Dividend

What is Poly Medicure's current dividend yield, its reliability and sustainability?

0.69%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: POLYMED's dividend (0.69%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.85%).

High Dividend: POLYMED's dividend (0.69%) is low compared to the top 25% of dividend payers in the Indian market (3.65%).


Stability and Growth of Payments

Stable Dividend: POLYMED's dividend payments have been volatile in the past 10 years.

Growing Dividend: POLYMED's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (18.6%), POLYMED's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.3yrs

Average board tenure


CEO

Himanshu Baid (51yo)

24.67yrs

Tenure

₹44,301,000

Compensation

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect t ...


CEO Compensation Analysis

Compensation vs Market: Himanshu's total compensation ($USD583.49K) is above average for companies of similar size in the Indian market ($USD346.99K).

Compensation vs Earnings: Himanshu's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Himanshu Baid
CEO, MD & Director24.67yrs₹44.30m13.31% 3.4b
Jugal Baid
Founder & Non Executive Director25.17yrs₹975.00k2.58% 660.7m
Rishi Baid
Joint MD & Executive Director25.17yrs₹43.27m14.47% 3.7b
Devendra Mehta
Independent Chairmanno data₹1.10mno data
Prakash Surana
Non-Executive Independent Director22.67yrs₹925.00k0.0024% 608.8k
Mukulika Baid
Non-Executive Director5.83yrs₹975.00k3.47% 887.6m
Shailendra Mehta
Non-Executive Independent Director8yrs₹1.08mno data
Sandeep Bhargava
Non-Executive Independent Director3.25yrs₹975.00kno data
Alessandro Balboni
Non-Executive Non Independent Director2yrsno datano data

15.3yrs

Average Tenure

60yo

Average Age

Experienced Board: POLYMED's board of directors are seasoned and experienced ( 15.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: POLYMED insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Poly Medicure Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Poly Medicure Limited
  • Ticker: POLYMED
  • Exchange: NSEI
  • Founded: 1995
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: ₹25.578b
  • Shares outstanding: 88.25m
  • Website: https://www.polymedicure.com

Number of Employees


Location

  • Poly Medicure Limited
  • 232B Okhla Industrial Estate
  • 3rd Floor
  • New Delhi
  • Delhi
  • 110020
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
531768BSE (Mumbai Stock Exchange)YesEquity SharesININRNov 2004
POLYMEDNSEI (National Stock Exchange of India)YesEquity SharesININRNov 2004
531768BSE (Mumbai Stock Exchange)INR5ININRFeb 2015
POLYMEDNSEI (National Stock Exchange of India)INR5ININRFeb 2015

Biography

Poly Medicure Limited manufactures and sells medical devices in India and internationally. It offers infusion devices, such as I.V. cannulas, needle free connectors, three way stop cocks, I.V. infusion sets and flow regulators, extension lines, Y-type infusion and transfusion sets, T-type extension sets, injection stoppers, luer lock injection sites, and safety winged infusion sets; and central venous catheters and CVP manometers. The company also provides anesthesia devices, including suction and oxygen catheters, oxygen and aerosol therapy masks, nasocath cannulas, catheter mounts, guedel airways, respiratory exercisers, endotracheal and tracheostomy tubes, spinal needles, and fixed concentration masks; gastroenterology products, such as Ryle’s and Levin’s tubes, infant feeding tubes, feeding bags, T tubes, stomach tubes, and umbilical catheters; and urology devices comprising urine collection bags, measured volume meters, urine drainage catheters, TUR sets, Foley balloon catheters, and irrigation sets. In addition, it offers blood administration sets, blood bag systems, transfusion pump sets, blood bags with safety device and sampling bags, CPD-SAGM-TOTM bag systems, top and bottom extraction bag systems, ACD bags, and safety blood collection sets; surgery and wound drainage devices, such as redon drains, thoracic drainage catheters, abdominal drainage sets, under water seal drainage systems and bottles, yankaur suction sets and handles, colostomy bags, closed wound suction units, and high pressure vacuum bottles with extension tubes. Further, it provides dialysis products, including fistula needles, haemodialysis catheters, peritoneal dialysis and transfusion sets, and haem-o-lines; mucus extractors, umbilical cord clamps, insulin syringes, sputum collectors, and dry brushes; blood collection tubes and needles; and safety arterial catheters, dialyzers, flashback needles, and manifolds. Poly Medicure Limited was founded in 1995 and is based in New Delhi, India. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/28 13:21
End of Day Share Price2020/05/28 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.